Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn's experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/28/20 | $35,500,000 | Series B |
F-Prime Capital Partners Norwest Venture Partners  Novo Holdings Pivotal bioVenture Partners RiverVest Venture Partners TPG Biotech | undisclosed |
| 09/29/23 | $175,000,000 | Series C |
Catalio Capital Management Eventide Asset Management F-Prime Capital Partners Norwest Venture Partners Novo Holdings Perceptive Xontogeny Venture Fund Piper Heartland Healthcare Capital Pivotal bioVenture Partners RiverVest Venture Partners Rock Springs Capital SR One Surveyor Capital T. Rowe Price Associates Vida Ventures Wellington Management | undisclosed |
